Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course

References

• HumbertMSitbonOSimonneauGTreatment of pulmonary arterial hypertensionN Engl J Med2004351141425143615459304
   PubMed Web of Science ®Google Scholar
• GalièNHoeperMMHumbertMESC Committee for Practice Guidelines (CPG)Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)Eur Heart J200930202493253719713419
   PubMed Web of Science ®Google Scholar
• SimonneauGGatzoulisMAAdatiaIUpdated clinical classification of pulmonary hypertensionJ Am Coll Cardiol20136225 SupplD34D4124355639
   PubMed Web of Science ®Google Scholar
• ChinKMKimNHRubinLJThe right ventricle in pulmonary hypertensionCoron Artery Dis2005161131815654194
   PubMed Web of Science ®Google Scholar
• BenzaRLMillerDPGomberg-MaitlandMPredicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)Circulation2010122216417220585012
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSMSurvival in patients with primary pulmonary hypertension. Results from a national prospective registryAnn Intern Med199111553433491863023
   PubMed Web of Science ®Google Scholar
• BogaardHJAbeKVonk NoordegraafAVoelkelNFThe right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertensionChest2009135379480419265089
   PubMed Web of Science ®Google Scholar
• ChampionHCMichelakisEDHassounPMComprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implicationsCirculation200912011992100719752350
   PubMed Web of Science ®Google Scholar
• GalièNHoeperMMHumbertMTask Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC)European Respiratory Society (ERS)International Society of Heart and Lung Transplantation (ISHLT)Guidelines for the diagnosis and treatment of pulmonary hypertensionEur Respir J20093461219126319749199
   PubMed Web of Science ®Google Scholar
• McLaughlinVVMcGoonMDPulmonary arterial hypertensionCirculation2006114131417143117000921
   PubMed Web of Science ®Google Scholar
• LeRJFenstadERMaradit-KremersHSyncope in adults with pulmonary arterial hypertensionJ Am Coll Cardiol201158886386721835323
   PubMedGoogle Scholar
• HumbertMSitbonOChaouatASurvival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management eraCirculation2010122215616320585011
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMNunesHLong-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalJ Am Coll Cardiol200240478078812204511
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShillingtonARichSSurvival in primary pulmonary hypertension: the impact of epoprostenol therapyCirculation2002106121477148212234951
   PubMed Web of Science ®Google Scholar
• DimopoulosKInuzukaRGolettoSImproved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertensionCirculation20101211202520026774
   PubMed Web of Science ®Google Scholar
• LaunayDSitbonOLe PavecJLong-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafilRheumatology (Oxford)201049349050020015974
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function LaboratoriesATS statement: guidelines for the six-minute walk testAm J Respir Crit Care Med2002166111111712091180
   PubMed Web of Science ®Google Scholar
• ProvencherSSitbonOHumbertMCabrolSJaïsXSimonneauGLong-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertensionEur Heart J200627558959516431875
   PubMed Web of Science ®Google Scholar
• WenselROpitzCFAnkerSDAssessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testingCirculation2002106331932412119247
   PubMed Web of Science ®Google Scholar
• McLaughlinVVGaineSPHowardLSTreatment goals of pulmonary hypertensionJ Am Coll Cardiol20136225 SupplD73D8124355644
   PubMed Web of Science ®Google Scholar
• McLaughlinVVArcherSLBadeschDBACCF/AHAACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension AssociationCirculation2009119162250229419332472
   PubMed Web of Science ®Google Scholar
• NickelNGolponHGreerMThe prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertensionEur Respir J201239358959621885392
   PubMed Web of Science ®Google Scholar
• MiuraYFukumotoYSugimuraKIdentification of new prognostic factors of pulmonary hypertensionCirc J20107491965197120631450
   PubMed Web of Science ®Google Scholar
• HoeperMMPletzMWGolponHWelteTPrognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertensionEur Respir J200729594495017301100
   PubMed Web of Science ®Google Scholar
• BadanoLPGinghinaCEasawJRight ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effectsEur J Echocardiogr2010111273719815539
   PubMed Web of Science ®Google Scholar
• MillerDFarahMGLinerAFoxKSchluchterMHoitBDThe relation between quantitative right ventricular ejection fraction and indices of tricuspid annular motion and myocardial performanceJ Am Soc Echocardiogr200417544344715122184
   PubMed Web of Science ®Google Scholar
• ForfiaPRFisherMRMathaiSCTricuspid annular displacement predicts survival in pulmonary hypertensionAm J Respir Crit Care Med200617491034104116888289
   PubMed Web of Science ®Google Scholar
• TeiCDujardinKSHodgeDODoppler echocardiographic index for assessment of global right ventricular functionJ Am Soc Echocardiogr1996968388478943444
   PubMedGoogle Scholar
• YeoTCDujardinKSTeiCMahoneyDWMcGoonMDSewardJBValue of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertensionAm J Cardiol1998819115711619605059
   PubMed Web of Science ®Google Scholar
• GrapsaIPavlopoulosHDawsonDGibbsJSNihoyannopoulosPRetrospective study of pulmonary hypertensive patients: is right ventricular myocardial performance index a vital prognostic factor?Hellenic J Cardiol200748315216017629178
   PubMedGoogle Scholar
• López-CandalesARajagopalanNSaxenaNGulyasyBEdelmanKBazazRRight ventricular systolic function is not the sole determinant of tricuspid annular motionAm J Cardiol200698797397716996886
   PubMed Web of Science ®Google Scholar
• GhioSKlersyCMagriniGPrognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertensionInt J Cardiol2010140327227819070379
   PubMed Web of Science ®Google Scholar
• TorbickiACardiac magnetic resonance in pulmonary arterial hypertension: a step in the right directionEur Heart J200728101187118917483527
   PubMedGoogle Scholar
• van WolferenSAMarcusJTBoonstraAPrognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertensionEur Heart J200728101250125717242010
   PubMed Web of Science ®Google Scholar
• YamadaYOkudaSKataokaMPrognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapyCirc J20127671737174322498565
   PubMed Web of Science ®Google Scholar
• TorbickiAKurzynaMKucaPDetectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertensionCirculation2003108784484812900346
   PubMed Web of Science ®Google Scholar
• NagayaNNishikimiTUematsuMPlasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertensionCirculation2000102886587010952954
   PubMed Web of Science ®Google Scholar
• MauritzGJRizopoulosDGroepenhoffHUsefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertensionAm J Cardiol2011108111645165021890089
   PubMedGoogle Scholar
• WilliamsMHHandlerCEAkramRRole of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertensionEur Heart J200627121485149416682379
   PubMed Web of Science ®Google Scholar
• NagayaNUematsuMSatohTSerum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertensionAm J Respir Crit Care Med1999160248749210430718
   PubMed Web of Science ®Google Scholar
• TaguchiHKataokaMYanagisawaRPlatelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapyCirc J20127661494150022447010
   PubMed Web of Science ®Google Scholar
• PriceLCWortSJPerrosFInflammation in pulmonary arterial hypertensionChest2012141121022122215829
   PubMed Web of Science ®Google Scholar
• CracowskiJLChabotFLabarèreJProinflammatory cytokine levels are linked to death in pulmonary arterial hypertensionEur Respir J201443391591724232704
   PubMedGoogle Scholar
• HeresiGAAytekinMHammelJPWangSChatterjeeSDweikRAPlasma interleukin-6 adds prognostic information in pulmonary arterial hypertensionEur Respir J201443391291424136333
   PubMedGoogle Scholar
• BenzaRLMillerDPBarstRJBadeschDBFrostAEMcGoonMDAn evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL RegistryChest2012142244845622281797
   PubMed Web of Science ®Google Scholar
• BenzaRLGomberg-MaitlandMMillerDPThe REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertensionChest2012141235436221680644
   PubMed Web of Science ®Google Scholar
• HumbertMSitbonOYaïciAFrench Pulmonary Arterial Hypertension NetworkSurvival in incident and prevalent cohorts of patients with pulmonary arterial hypertensionEur Respir J201036354955520562126
   PubMed Web of Science ®Google Scholar
• ThenappanTShahSJRichSTianLArcherSLGomberg-MaitlandMSurvival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equationEur Respir J20103551079108720032020
   PubMed Web of Science ®Google Scholar
• BarstRJGibbsJSGhofraniHAUpdated evidence-based treatment algorithm in pulmonary arterial hypertensionJ Am Coll Cardiol2009541 SupplS78S8419555861
   PubMed Web of Science ®Google Scholar
• GalièNTorbickiABarstRTask ForceGuidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J200425242243227815589643
   PubMed Web of Science ®Google Scholar
• BadeschDBAbmanSHSimonneauGRubinLJMcLaughlinVVMedical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelinesChest200713161917192817565025
   PubMed Web of Science ®Google Scholar
• KataokaMNagayaNSatohTA long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertensionAm J Respir Crit Care Med2005172121575158016192456
   PubMedGoogle Scholar
• GiaidAYanagisawaMLanglebenDExpression of endothelin-1 in the lungs of patients with pulmonary hypertensionN Engl J Med199332824173217398497283
   PubMed Web of Science ®Google Scholar
• MehtaSSildenafil for pulmonary arterial hypertension: exciting, but protection requiredChest2003123498999212684284
   PubMedGoogle Scholar
• BarstRJRubinLJLongWAPrimary Pulmonary Hypertension Study GroupA comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertensionN Engl J Med199633452963018532025
   PubMed Web of Science ®Google Scholar
• SitbonOMcLaughlinVVBadeschDBSurvival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolThorax200560121025103016055621
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonOEffects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJBosentan therapy for pulmonary arterial hypertensionN Engl J Med20023461289690311907289
   PubMed Web of Science ®Google Scholar
• GalièNBrundageBHGhofraniHAPulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study GroupTadalafil therapy for pulmonary arterial hypertensionCirculation2009119222894290319470885
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDBadeschDSTRIDE-2 Study GroupTreatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentanJ Am Coll Cardiol200647102049205616697324
   PubMed Web of Science ®Google Scholar
• GalièNRubinLjHoeperMTreatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialLancet200837196302093210018572079
   PubMed Web of Science ®Google Scholar
• HumbertMBarstRJRobbinsIMCombination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J200424335335915358690
   PubMed Web of Science ®Google Scholar
• HoeperMMLeuchteHHalankMCombining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertensionEur Respir J200628469169417012628
   PubMed Web of Science ®Google Scholar
• SimonneauGRubinLJGalièNPACES Study GroupAddition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trialAnn Intern Med2008149852153018936500
   PubMed Web of Science ®Google Scholar
• SitbonOJaïsXSavaleLUpfront triple combination therapy in pulmonary arterial hypertension: a pilot studyEur Respir J20144361691169724627535
   PubMed Web of Science ®Google Scholar
• SitbonOSimonneauGOptimal management of severe pulmonary arterial hypertensionEur Respir Rev20112012225426122130818
   PubMedGoogle Scholar
• KurzynaMDabrowskiMBieleckiDAtrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertensionChest2007131497798317426198
   PubMed Web of Science ®Google Scholar
• ReichenbergerFPepke-ZabaJMcNeilKParameshwarJShapiroLMAtrial septostomy in the treatment of severe pulmonary arterial hypertensionThorax200358979780012947142
   PubMed Web of Science ®Google Scholar
• DoyleRLMcCroryDChannickRNSimonneauGConteJAmerican College of Chest PhysiciansSurgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelinesChest20041261 Suppl63S71S15249495
   PubMed Web of Science ®Google Scholar
• KeoghAMMayerEBenzaRLInterventional and surgical modalities of treatment in pulmonary hypertensionJ Am Coll Cardiol2009541 SupplS67S7719555860
   PubMed Web of Science ®Google Scholar
• SandovalJRothmanAPulidoTAtrial septostomy for pulmonary hypertensionClin Chest Med200122354756011590848
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShillingtonARichSSurvival in primary pulmonary hypertension: the impact of epoprostenol therapyCirculation2002106121477148212234951
   PubMed Web of Science ®Google Scholar
• SitbonOHumbertMSimonneauGPrimary pulmonary hypertension: current therapyProg Cardiovasc Dis200245211512812411973
   PubMed Web of Science ®Google Scholar
• TrulockEPChristieJDEdwardsLBRegistry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007J Heart Lung Transplant200726878279517692782
   PubMed Web of Science ®Google Scholar
• OrensJBEstenneMArcasoySPulmonary Scientific Council of the International Society for Heart and Lung TransplantationInternational guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung TransplantationJ Heart Lung Transplant200625774575516818116
   PubMed Web of Science ®Google Scholar
• DavisSQGarrityEROrgan allocation in lung transplantChest200713251646165117998365
   PubMed Web of Science ®Google Scholar
• IribarneARussoMJDaviesRRDespite decreased wait-list times for lung transplantation, lung allocation scores continue to increaseChest2009135492392819017874
   PubMedGoogle Scholar
• SitbonOGalièNTreat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goalsEur Respir Rev20101911827227821119185
   PubMedGoogle Scholar
• HoeperMMMarkevychISpiekerkoetterEWelteTNiedermeyerJGoal-oriented treatment and combination therapy for pulmonary arterial hypertensionEur Respir J200526585886316264047
   PubMed Web of Science ®Google Scholar
• MubarakKKA review of prostaglandin analogs in the management of patients with pulmonary arterial hypertensionRespir Med2010104192119683911
   PubMed Web of Science ®Google Scholar
• ChristmanBWMcPhersonCDNewmanJHAn imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertensionN Engl J Med1992327270751603138
   PubMed Web of Science ®Google Scholar
• TuderRMCoolCDGeraciMWProstacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertensionAm J Respir Crit Care Med199915961925193210351941
   PubMed Web of Science ®Google Scholar
• AbramovitzMAdamMBoieYThe utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogsBiochim Biophys Acta20001483228529310634944
   PubMed Web of Science ®Google Scholar
• KuwanoKHashinoAAsakiT2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino] butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrugJ Pharmacol Exp Ther200732231181118817545310
   PubMed Web of Science ®Google Scholar
• TapsonVFTorresFKermeenFOral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trialChest201214261383139022628490
   PubMed Web of Science ®Google Scholar
• TapsonVFJingZCXuKFFREEDOM-C2 Study TeamOral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trialChest2013144395295823669822
   PubMed Web of Science ®Google Scholar
• JingZCParikhKPulidoTEfficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trialCirculation2013127562463323307827
   PubMed Web of Science ®Google Scholar
• RichJHoeperMMThe search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?Int J Clin Pract Suppl2009161171819178601
   PubMedGoogle Scholar
• IkedaDTsujinoISakaueSPilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertensionCirc J200771111829183117965512
   PubMedGoogle Scholar
• ArmstrongDJBenzaRLDelcroixMClinical pharmacology and safety of beraprost sodium modified release (BPS-MR), an oral twice daily prostacyclin analogue – a phase II study [abstract]Am J Respir Crit Care Med2010181A3360
   Web of Science ®Google Scholar
• MorrisonKErnstRHessPStuderRClozelMSelexipag: a selective prostacyclin receptor agonist that does not affect rat gastric functionJ Pharmacol Exp Ther2010335124925520660124
   PubMed Web of Science ®Google Scholar
• SimonneauGTorbickiAHoeperMMSelexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertensionEur Respir J201240487488022362844
   PubMed Web of Science ®Google Scholar
• DupuisJEndothelin: setting the scene in PAHEur Respir Rev20071610237
   Google Scholar
• GaliéNManesABranziAThe endothelin system in pulmonary arterial hypertensionCardiovasc Res200461222723714736539
   PubMed Web of Science ®Google Scholar
• IglarzMClozelMAt the heart of tissue: endothelin system and end-organ damageClin Sci (Lond)20101191145346320712600
   PubMedGoogle Scholar
• PulidoTAdzerikhoIChannickRNSERAPHIN InvestigatorsMacitentan and morbidity and mortality in pulmonary arterial hypertensionN Engl J Med2013369980981823984728
   PubMed Web of Science ®Google Scholar
• BrudererSAänismaaPHomeryMCEffect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonistAAPS J2012141687822189899
   PubMed Web of Science ®Google Scholar
• SidhartaPNAtsmonJDingemanseJInvestigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjectsBr J Clin Pharmacol201070930931
   Google Scholar
• IgnarroLJBugaGMWoodKSByrnsREChaudhuriGEndothelium- derived relaxing factor produced and released from artery and vein is nitric oxideProc Natl Acad Sci U S A19878424926592692827174
   PubMed Web of Science ®Google Scholar
• ArnoldWPMittalCKKatsukiSMuradFNitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparationsProc Natl Acad Sci U S A19777483203320720623
   PubMed Web of Science ®Google Scholar
• GhofraniHAOsterlohIHGrimmingerFSildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyondNat Rev Drug Discov20065868970216883306
   PubMed Web of Science ®Google Scholar
• GrimmingerFWeimannGFreyRFirst acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEur Respir J200933478579219129292
   PubMed Web of Science ®Google Scholar
• GhofraniHAGalièNGrimmingerFPATENT-1 Study GroupRiociguat for the treatment of pulmonary arterial hypertensionN Engl J Med2013369433034023883378
   PubMed Web of Science ®Google Scholar
• GhofraniHAD’ArminiAMGrimmingerFCHEST-1 Study GroupRiociguat for the treatment of chronic thromboembolic pulmonary hypertensionN Engl J Med2013369431932923883377
   PubMed Web of Science ®Google Scholar
• BarstRJPDGF signaling in pulmonary arterial hypertensionJ Clin Invest2005115102691269416200204
   PubMed Web of Science ®Google Scholar
• PanosRJBakerSKMediators, cytokines, and growth factors in liver-lung interactionsClin Chest Med19961711511698665787
   PubMedGoogle Scholar
• SchermulyRTDonyEGhofraniHAReversal of experimental pulmonary hypertension by PDGF inhibitionJ Clin Invest2005115102811282116200212
   PubMed Web of Science ®Google Scholar
• ten FreyhausHDumitrescuDBerghausenEVantlerMCaglayanERosenkranzSImatinib mesylate for the treatment of pulmonary arterial hypertensionExpert Opin Investig Drugs2012211119134
   PubMed Web of Science ®Google Scholar
• HoeperMMBarstRJBourgeRCImatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES studyCirculation2013127101128113823403476
   PubMed Web of Science ®Google Scholar
• SongKWRifkindJAl-BeiroutiBSubdural hematomas during CML therapy with imatinib mesylateLeuk Lymphoma20044581633163615370217
   PubMed Web of Science ®Google Scholar
• KerkeläRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med200612890891616862153
   PubMed Web of Science ®Google Scholar
• GalièNCorrisPAFrostAUpdated treatment algorithm of pulmonary arterial hypertensionJ Am Coll Cardiol20136225 SupplD60D7224355643
   PubMed Web of Science ®Google Scholar